JP2012501313A5 - - Google Patents

Download PDF

Info

Publication number
JP2012501313A5
JP2012501313A5 JP2011524404A JP2011524404A JP2012501313A5 JP 2012501313 A5 JP2012501313 A5 JP 2012501313A5 JP 2011524404 A JP2011524404 A JP 2011524404A JP 2011524404 A JP2011524404 A JP 2011524404A JP 2012501313 A5 JP2012501313 A5 JP 2012501313A5
Authority
JP
Japan
Prior art keywords
amino
pyridin
cycloalkyl
quinazolin
difluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011524404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012501313A (ja
JP5584215B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/061188 external-priority patent/WO2010026122A1/en
Publication of JP2012501313A publication Critical patent/JP2012501313A/ja
Publication of JP2012501313A5 publication Critical patent/JP2012501313A5/ja
Application granted granted Critical
Publication of JP5584215B2 publication Critical patent/JP5584215B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011524404A 2008-09-02 2009-08-31 ヘテロ環pimキナーゼ阻害剤 Expired - Fee Related JP5584215B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9366408P 2008-09-02 2008-09-02
US61/093,664 2008-09-02
PCT/EP2009/061188 WO2010026122A1 (en) 2008-09-02 2009-08-31 Heterocyclic pim-kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2012501313A JP2012501313A (ja) 2012-01-19
JP2012501313A5 true JP2012501313A5 (enExample) 2012-10-11
JP5584215B2 JP5584215B2 (ja) 2014-09-03

Family

ID=41170173

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011524404A Expired - Fee Related JP5584215B2 (ja) 2008-09-02 2009-08-31 ヘテロ環pimキナーゼ阻害剤

Country Status (11)

Country Link
US (1) US8759338B2 (enExample)
EP (1) EP2344473B1 (enExample)
JP (1) JP5584215B2 (enExample)
KR (1) KR20110056399A (enExample)
CN (1) CN102197032B (enExample)
AU (1) AU2009289317A1 (enExample)
BR (1) BRPI0918846A2 (enExample)
CA (1) CA2735782A1 (enExample)
EA (1) EA201100427A1 (enExample)
MX (1) MX2011002362A (enExample)
WO (1) WO2010026122A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
HUE029236T2 (en) 2007-06-13 2017-02-28 Incyte Holdings Corp (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
MY156727A (en) 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2432472B1 (en) 2009-05-22 2019-10-02 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
AR084691A1 (es) 2010-05-21 2013-06-05 Incyte Corp Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
EP2734205B1 (en) 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
TWI761825B (zh) 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
MX384910B (es) 2013-03-06 2025-03-14 Incyte Holdings Corp Procesos e intermedios para hacer un inhibidor de jak.
SG11201600815WA (en) 2013-08-07 2016-03-30 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
TW201605866A (zh) 2013-08-23 2016-02-16 英塞特公司 可用作pim激酶抑制劑之呋喃并-及噻吩并-吡啶甲醯胺化合物
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN108373476B (zh) * 2017-01-13 2021-06-01 成都地奥制药集团有限公司 一种激酶抑制剂及其制备和应用
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
JP7393348B2 (ja) 2018-01-30 2023-12-06 インサイト・コーポレイション (1-(3-フルオロ-2(トリフルオロメチル)イソニコチニル)ピぺリジン―4-オン)を作製するためのプロセス及び中間体
CN113768934A (zh) 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
CA3095580A1 (en) 2018-04-13 2019-10-17 Sumitomo Dainippon Pharma Oncology, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
CN109369513B (zh) * 2018-11-20 2020-08-25 都创(上海)医药科技有限公司 一种fbdd常用分子片段的制备方法
CN111362922A (zh) * 2018-12-26 2020-07-03 上海喆邺生物科技有限公司 2,4-二氨基嘧啶衍生物及其用途
AU2020221247B2 (en) 2019-02-12 2024-12-12 Sumitomo Pharma America, Inc. Formulations comprising heterocyclic protein kinase inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk﹘5抑制劑和彼之用途
JP2026509318A (ja) 2022-10-31 2026-03-18 スミトモ・ファーマ・アメリカ・インコーポレイテッド 骨髄増殖性新生物を治療するためのpim1阻害剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9312891D0 (en) 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB0226724D0 (en) * 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
WO2004081000A1 (en) 2003-03-10 2004-09-23 Astrazeneca Ab Quinazoline derivatives
WO2004108707A1 (en) 2003-06-05 2004-12-16 Astrazeneca Ab Pyridazinil quinazoline derivatives for use in the treatment of tumours
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
MXPA06003615A (es) * 2003-09-30 2006-06-05 Amgen Inc Ligandos del receptor vanilloide y su uso en tratamientos.
US7781591B2 (en) * 2006-06-13 2010-08-24 Wyeth Llc Substituted 3-cyanopyridines as protein kinase inhibitors
CA2569404A1 (en) * 2004-06-04 2005-12-22 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
ATE528302T1 (de) * 2005-08-29 2011-10-15 Vertex Pharma 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
TW200815407A (en) 2006-06-13 2008-04-01 Wyeth Corp Substituted 3-cyanopyridines as protein kinase inhibitors
US7956064B2 (en) 2006-09-01 2011-06-07 Cylene Pharmaceuticals, Inc. Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
WO2008153947A2 (en) * 2007-06-07 2008-12-18 Amgen Inc. Heterocyclic compounds as raf kinase modulators

Similar Documents

Publication Publication Date Title
JP2012501312A5 (enExample)
RU2436776C2 (ru) ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT
RU2498983C2 (ru) Соединения фениламинопиримидина и их применения
JP2017525757A5 (enExample)
HRP20191821T1 (hr) Antiproliferativni spojevi i načini njihove uporabe
RU2500673C2 (ru) Гетероциклические ингибиторы мек и способы их применения
JP2019533694A5 (enExample)
JP2007519754A5 (enExample)
JP2011504497A5 (enExample)
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
JP2014506599A5 (enExample)
US20040192701A1 (en) Phenlypyridine carbonyl piperazine derivative
HRP20201430T1 (hr) Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa
JP2014511869A5 (enExample)
RU2007132262A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
JP2016530310A5 (enExample)
JP2010526129A5 (enExample)
RU2009148673A (ru) Производные пиразинона и их применение для лечения легочных заболеваний
JP2010534654A5 (enExample)
JP2009506039A5 (enExample)
JP2009542721A5 (enExample)
JP2003528859A5 (enExample)
JP2012503018A5 (enExample)
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
NZ627750A (en) Carbamate compounds and of making and using same